Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes.

12 сент. 2024 г. · Once-weekly subcutaneous semaglutide was associated with a decreased risk of MACE comprised of CV death, nonfatal MI, and stroke compared with placebo.

24 авг. 2024 г. · Patients recruited to SELECT had established astherosclerotic cardiovascular disease with one or more of previous myocardial infarction, stroke, ...

13 мая 2024 г. · In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with ...

14 дек. 2023 г. · A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients ( ...

3 нояб. 2024 г. · New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or ...

25 мая 2024 г. · The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n ...

11 нояб. 2023 г. · The SELECT Trial GLP-1 receptor agonists have been proven to reduce body weight and lessen CV risk in patients with type 2 diabetes, but—until ...

3 нояб. 2024 г. · Semaglutide 2.4 mg significantly reduced hospital admissions and overall length of hospital stay for adults with obesity or overweight with established ...

13 мая 2024 г. · The results of the SELECT trial were first published in November 2023. It included over 17,000 patients who (a) were overweight or obese, (b) ...